Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Charles River Laboratories International, Inc.    CRL

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

(CRL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.
Strengths
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Historically, the company has been releasing figures that are above expectations.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The stock is in a well-established, long-term rising trend above the technical support level at 169.98 USD
Weaknesses
  • The stock is close to a major daily resistance at USD 276.31, which should be gotten rid of so as to gain new appreciation potential.
  • The company's enterprise value to sales, at 5.25 times its current sales, is high.
  • The company benefits from high valuations in earnings multiples.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
CHARLES RIVER LABORATORIES ..9.55%13 616
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-12.53%40 715
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601
HANGZHOU TIGERMED CONSULTIN..0.43%21 655
INCYTE CORPORATION4.12%19 832
ALNYLAM PHARMACEUTICALS, IN..28.00%19 328
PHARMARON BEIJING CO., LTD.5.47%15 119
CRISPR THERAPEUTICS AG30.55%14 233
BIO-TECHNE CORPORATION9.50%13 425
PPD, INC.6.66%12 762
QIAGEN N.V.0.66%12 098
ICON PUBLIC LIMITED COMPANY7.88%11 101
IONIS PHARMACEUTICALS, INC.8.38%8 568
More Results
Financials (USD)
Sales 2020 2 891 M - -
Net income 2020 296 M - -
Net Debt 2020 1 565 M - -
P/E ratio 2020 46,5x
Yield 2020 -
Capitalization 13 616 M 13 616 M -
EV / Sales 2020 5,25x
EV / Sales 2021 4,62x
Nbr of Employees 17 100
Free-Float 98,2%
Upcoming event on CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes